

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 October 2020 (08.10.2020)



(10) International Publication Number
WO 2020/205932 A1

(51) International Patent Classification:

A61K 31/69 (2006.01) C07F 5/02 (2006.01)
A61P 31/04 (2006.01)

(21) International Application Number:

PCT/US2020/026114

(22) International Filing Date:

01 April 2020 (01.04.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/828,349 02 April 2019 (02.04.2019) US

(71) Applicant: **VENATORX PHARMACEUTICALS, INC.**
[US/US]; 30 Spring Mill Drive, Malvern, Pennsylvania
19355 (US).

(72) Inventors: **BURNS, Christopher J.**; 30 Spring Mill Drive,
Malvern, Pennsylvania 19355 (US). **ROSEN, Lawrence**;
30 Spring Mill Drive, Malvern, Pennsylvania 19355 (US).
CONDON, Stephen M.; 30 Spring Mill Drive, Malvern,
Pennsylvania 19355 (US). **MESAROS, Eugen F.**; 30


Spring Mill Drive, Malvern, Pennsylvania 19355 (US).
ZULLI, Allison L.; 30 Spring Mill Drive, Malvern, Penn-
sylvania 19355 (US). **TROUT, Robert E. Lee**; 30 Spring
Mill Drive, Malvern, Pennsylvania 19355 (US). **DENG, Yi-
jun**; 30 Spring Mill Drive, Malvern, Pennsylvania 19355
(US). **BOYD, Steven A.**; 30 Spring Mill Drive, Malvern,
Pennsylvania 19355 (US). **SIMPSON, Robert**; 30 Spring
Mill Drive, Malvern, Pennsylvania 19355 (US).

(74) Agent: **BONNEFOUS, Celine M.**; WILSON SONSINI,
650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: SOLID FORMS OF AN ORALLY-DELIVERED BETA-LACTAMASE INHIBITOR AND USES THEREOF

FIG. 4



(57) Abstract: Disclosed herein are crystalline forms of ((2-Ethylbutanoyl)oxy)methyl (R)-2-hydroxy-3-propionamido-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylate. Also disclosed herein are methods of treating a bacterial with a crystalline form of ((2-Ethylbutanoyl)oxy)methyl (R)-2-hydroxy-3-propionamido-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylate.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*